ATRA
insider transactionsAtara Biotherapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-7.7K
0 buy · 7.7K sell
Net value · 90d
-$69.9K
$0 in · $69.9K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
2
0 buy · 7.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Nguyen AnhCo KEY
President and CEO
$47.8K
5.2K sh · $9.13
Own -4%
-
Sell·S
Chief Accounting Officer
$22.0K
2.4K sh · $9.13
Own -5%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 18, 2026 | Nguyen AnhCo KEY | Sell S | 5.2K | $47.8K |
| May 18, 2026 | Grant-Huerta Yanina | Sell S | 2.4K | $22.0K |
About ATRA insider trading
This page tracks insider transactions for Atara Biotherapeutics, Inc. (ATRA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.